Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

TB test accepted for ‘exceptional private use’
Actiphage is a six-hour test that can identify the presence of live mycobacteria in blood or milk samples.
BVA welcomes move that could improve testing accuracy

A novel test for bovine TB that is more sensitive than previous methods has been accepted for ‘exceptional private use’ in England.

Actiphage is a six-hour test that can identify the presence of live mycobacteria in blood or milk samples. The currently approved skin test for bovine TB assesses the animal’s response to the bacteria and results take 72 hours.

Under the new ‘exceptional private use’ protocol, Actiphage can be used on a small number of large, persistently-infected herds. Before it can be given the go-ahead for veterinary use, however, it will need to go through further trials.

The news has been welcomed by the British Veterinary Association (BVA). BVA president John Fishwick said:

“We welcome any test that could improve the accuracy of diagnosing bovine TB and it is heartening to hear that this new test could potentially provide quicker, more convenient results.

“With any TB test, it is absolutely crucial that its sensitivity, specify and performance are fully understood and it is reassuring that the Animal and Plant Health Agency have authorised the exceptional private use of this test to it will be used appropriately at this stage of its development.

“TB testing is an important tool that can help achieve the long-term goal of TB eradication and must be part of a comprehensive toolkit of measures.”

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.